



ASX ANNOUNCEMENT

20 May 2019

Cynata Therapeutics Strengthens Board and Executive Management Team

Venture capital veteran Dr Geoff Brooke appointed as director to the Board

Dr Suzanne Lipe appointed as Vice President, Alliance Management

Dr Kilian Kelly promoted to Chief Operating Officer

Melbourne, Australia; 20 May 2019: Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, announced today that healthcare industry and venture capital veteran, Dr Geoff Brooke, has been appointed as an independent non-executive director to the Board of the Company. Dr Brooke's 30 years of international experience adds substantial life sciences and financial expertise to the Cynata Board. Dr Brooke is the founder and former Managing Director of two leading life sciences venture capital firms, GBS Ventures and Medvest Inc, as well as the lead investor and Chairman/Director of numerous healthcare companies.

The Company is also pleased to announce the appointment of Dr Suzanne Lipe to the new role of Vice President, Alliance Management. Dr Lipe has had a distinguished career in biotechnology and pharmaceutical companies for more than 20 years, including highly relevant experience in stem cell therapeutics and regenerative medicine as former Vice President Operations at Mesoblast. She has a PhD in pharmacology and a Bachelor of Laws. Dr Lipe's background and network will be important in driving the Company's growing commercial activities.

Additionally, in recognition of his outstanding achievements and the further development of Cynata's organisation, Dr Kilian Kelly has been promoted to the new role of Chief Operating Officer.

Dr Paul Wotton, Cynata's Chairman:

"Geoff Brooke brings extensive and broad-based experience across the Australian and US-listed healthcare space, as well as outstanding connections in the capital markets. This is now particularly relevant as Cynata continues to execute on its commercial partnering plans and expands its product development activities to multiple planned Phase 2 clinical trials. The strengthening of the management team also builds a firm foundation for this next exciting phase of Cynata's growth."

Dr Ross Macdonald, Cynata's Managing Director and Chief Executive Officer:

"Supporting the growth of Cynata and the Company's continued success has been a key goal for me, and I am delighted to strengthen the Company at the executive and non-executive levels with these new appointments. I am confident that Geoff and Suzanne will make many positive contributions to Cynata's progress."

Dr John Chiplin, who has been a non-executive director of Cynata since October 2014, has stepped down from the Board. The Company extends warm thanks and appreciation to John for his role in building the Company from its early days post-IPO to the enterprise it is today.

As a condition of his appointment, Dr Brooke has been granted 300,000 options. The exercise price of the options will be \$2.11 per option (a 75% premium to the VWAP during the 1 week up to and including the date of his appointment). The options will expire on 16 May 2024, with 100,000 options



vesting immediately and 100,000 options vesting 12 months from the date of his appointment and 100,000 options vesting 24 months from the date of his appointment (in each case subject to his continuous service to the Company as a non-executive Director during the period from the date of grant up to and including the applicable vesting date).

The Company has also agreed to grant a total of 1,425,000 options under the Employee Incentive Option Plan at an exercise price of \$1.75 per option (a 45% premium to the VWAP during the 1 week up to and including the date of approval by the Board) to members of the management team (not including Directors) in the following amounts: 375,000 to Dr Lipe, 750,000 to Dr Kelly and 300,000 to Senior Project Manager Dr Lynne Atley, who joined the Company in November 2018. The options will expire on 16 May 2022. Each employee's options will vest in three equal tranches, one third immediately upon grant (except for Dr Lipe, whose first one-third vest 3 months from the commencement date of her employment), one third 12 months from the grant date and one third 24 months from the grant date. The options will only vest subject to continuous service by the employee up to the applicable vesting date, and will expire three years from the date of approval by the Board.

Ends

CONTACTS: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, ross.macdonald@cynata.com
Rosa Smith, Australia Media Contact, +61 (0) 475 305 047, rosa.smith@mcpartners.com.au
Claire LaCagnina, U.S. Media Contact, +1 315.765.1462, clacagnina@6degreespr.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale and without the limitation of multiple donors.

Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Cynata plans to advance its Cymerus™ MSCs into Phase 2 trials for GvHD, critical limb ischemia and osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of asthma, diabetic wounds, heart attack and cytokine release syndrome, a life-threatening condition stemming from cancer immunotherapy.